Producing Labeled Antigens Patents (Class 436/544)
-
Patent number: 5118612Abstract: An immunoassay for trichothecenes that have at least three hydroxyl groups at specified positions is disclosed. It relies on developing antibodies to close trichothecene variants that are missing at least one of the hydroxyl groups, and then using these antibodies to test specimens in which the trichothecene has been converted to the variant (usually to the OAC variant). For example, DON and T-2 tetraol can be assayed for using this invention.Type: GrantFiled: August 28, 1989Date of Patent: June 2, 1992Assignee: Wisconsin Alumni Research FoundationInventors: Fun S. Chu, Ru-Dong Wei, Guang S. Zhang
-
Patent number: 5106762Abstract: Ligand-label conjugates which are an oligopeptide of 5 to 100 amino acid residues, bonded to a ligand or receptor, which contain a plurality of chemiluminescent or fluorescent labels and a plurality of polyoxoanions of sulfur or phosphorus are useful for immunoassays. Such conjugates are hydrophilic and exhibit very low nonspecific binding, thereby significantly increasing the signal to background ratio in immunoassays.Type: GrantFiled: April 20, 1990Date of Patent: April 21, 1992Assignee: Georgetown UniversityInventors: Reinhard Bredehorst, Frances S. Ligler, Anne W. Kusterbeck, Gregory A. Wemhoff, Carl-Wilhelm Vogel
-
Patent number: 5100807Abstract: The present invention is directed to a fluorescence polarization immunoassay for determining the phenylacetylglutamine (PAG) content in body fluids, to the various components needed for preparing and carrying out such an assay, and to the methods of making these components. Specifically, tracers, immunogens and antibodies are disclosed, as well as methods for preparing them. The assay is conducted by measuring the degree of polarization of plane polarized light that has been passed through a solution continuing sample, antiserum and tracer.Type: GrantFiled: October 19, 1987Date of Patent: March 31, 1992Assignee: Abbott LaboratoriesInventors: Maciej B. Adamczyk, Hossein A. Ghanbari, Donald D. Johnson
-
Patent number: 5099000Abstract: A substituted monoethylglycinexylidide or analogue is disclosed. The xylidide or analogue has the structure of FIG. 1 of the attached drawings where M is CH.sub.2 NHCH.sub.2 CH.sub.3, CH.sub.2 CH.sub.2 CH.sub.2 CH.sub.3 or CH.sub.2 OCH.sub.2 CH.sub.3, one of Y.sup.1 and Y.sup.2 is H and the other is a protein or a fluorescein moiety chemcially bonded to the glycinexylidide or analogue moiety. Also disclosed is a method for carrying out immunoassays for MEGX, which has the structure of FIG. 3 of the attached drawings. The method for carrying out immunoassays involves using the foregoing compounds as tracers and immunogens.Type: GrantFiled: December 22, 1989Date of Patent: March 24, 1992Assignee: Abbott LaboratoriesInventors: Lawrence Kolaczkowski, Mark Littlefield
-
Patent number: 5093118Abstract: A cell wall protein of the fungus B. dermatitidis is isolated and purified. The protein is readily recognized by serum antibodies from animals having blastomycosis. The protein antigen can be labelled to provide an assay for detection of the disease, it can be used to stimulate specific lymphocyte response and thereby provide another assay for detection of the disease, it can be used to produce an immune response to B. dermatitidis, or it can be used to create antibodies to the protein.Type: GrantFiled: September 14, 1989Date of Patent: March 3, 1992Assignee: Wisconsin Alumni Research FoundationInventors: Bruce S. Klein, Jeffrey M. Jones
-
Patent number: 5089390Abstract: 2-methyl-4-hexene- and 3-methyl-5-heptene-1,2-diol derivatives are disclosed together with methods for preparing such derivatives. Where the derivative is a 2-methyl-4-hexene- or 3-methyl-5-heptene-1,2-diol conjugated to a label, the conjugates are useful in immunoassays. Where the 2-methyl-4-hexene or 3-methyl-5-heptene-1,2-diol is conjugated to an immunogenic carrier, the conjugates may be employed as an immunogen for use in the preparation of antibodies. The label conjugate and the antibodies can be utilized in an immunoassay for the determination or detection of cyclosporin in a sample suspected of containing cyclosporin.Type: GrantFiled: September 4, 1987Date of Patent: February 18, 1992Assignee: Syntex (U.S.A.) Inc.Inventors: Dariush Davalian, Cheng-I Lin, Edwin F. Ullman
-
Patent number: 5089388Abstract: Conjugates of salicylic acid and certain poly(amino acids), which are either antigenic or enzymes, are provided. Antibodies raised against the antigenic poly(amino acids) and the enzyme conjugates are used as reagents in immunoassays.Type: GrantFiled: February 21, 1986Date of Patent: February 18, 1992Assignee: Syntex (U.S.A.) Inc.Inventors: Prithipal Singh, Michael Prisbylla
-
Patent number: 5068227Abstract: Cyclodextrins can be coupled to biorecognition molecules such as antibodies. The cyclodextrins so coupled provide a cavity or complexation zone into which active agents such as labels, drugs and the like may be incorporated. The active agent forms a noncovalently bonded inclusion complex within the cavity of the cyclodextrin. It remains associated with the cyclodextrin and the coupled biorecognition molecule and thus can be delivered to the other half of the biospecific recognition pair. A process for producing these materials is also disclosed. The process includes the steps of activating a primary hydroxyl site on a cyclodextrin; linking a biorecognition molecule to the activated primary hydroxyl site on the cyclodextrin in either a direct covalent linkage or through a covalently linked spacer; and introducing a guest molecule (active agent) into the cavity of the derivatized cyclodextrin to form an inclusion complex.Type: GrantFiled: January 18, 1989Date of Patent: November 26, 1991Assignee: Cyclex, Inc.Inventor: Ned M. Weinshenker
-
Patent number: 5061641Abstract: A protein containing at least one pendant sulfhydryl group is directly radiolabeled with a radiometal which binds tightly to sulfhydryl groups, using one or more pendant sulfhydral groups on the protein as endogenous ligands and optionally using an exogenous ligand which binds tightly to the radiometal ion to further stabilize the chelate.Type: GrantFiled: April 1, 1988Date of Patent: October 29, 1991Assignee: Immunomedics, Inc.Inventors: Dan Shochat, Hans J. Hansen, Robert S. Wu
-
Patent number: 5051371Abstract: Substantially pure modified .beta..sub.2 -microglobulin (m.beta..sub.2 m) of the formula I ##STR1## wherein R.sub.1 is 24-amino acid residue, with the sequence Ile-Gln-Arg-Thr-Pro-Lys-Ile-Gln-Val-Tyr-Ser-Arg-His-Pro-Ala-Glu-Asn-Gly-Ly s-Ser-Asn-Phe-Leu-Asn, R.sub.2 is a 30-amino acid residue with the sequence Tyr-Val-Ser-Gly-Phe-His-Pro-Ser-Asp-Ile-Glu-Val-Asp-Leu-Leu-Lys-Asn-Gly-Gl u-Arg-Ile-Gly-Lys-Val-Glu-His-Ser-Asp-Leu-Ser, R.sub.3 is a 20-amino acid residue with the sequence Trp-Ser-Phe-Tyr-Leu-Leu-Tyr-Tyr-Glu-Phe-Thr-Pro-Thr-Glu-Lys-Asp-Glu-Tyr-Al a, R.sub.4 is a 19-amino acid residue with the sequence Arg-Val-Asn-His-Val-Thr-Leu-Ser-Gln-Pro-Lys-Ile-Val-Lys-Trp-Asp-Arg-Asp-Me t, X is Phe, Phe-Ser, or Phe-Ser-Lys, and Y is Asp, Lys-Asp, or Ser-Lys-Asp is disclosed. The presence of the protein in body fluids is a diagnostic and/or prognostic marker for the development of a variety of disorders such as different types of cancer and diseases involving the immune system. Also disclosed are specific anti-m.Type: GrantFiled: January 15, 1987Date of Patent: September 24, 1991Assignee: Noyo Nordisk A/SInventors: Mogens H. Nissen, Jesper Zeuthen, Flemming S. Larsen, Lars Thim, Mogens Christensen
-
Patent number: 5051361Abstract: This invention relates to a method for the immunoassay of AZT (3'-azido-3'-deoxythymidine), also known as zidovudine, in biological fluids such as serum, semen, plasma and urine, as well as other body fluids. The invention also includes (1) various novel analogs of AZT useful in preparing immunogens for antibodies to AZT and in preparing labeled AZT, (2) immunogens for antibodies to AZT, (3) monoclonal and polylonal antibodies to AZT, (4) labeled AZT analogs and (5) diagnostic test kits for the immunoassay.Type: GrantFiled: October 19, 1988Date of Patent: September 24, 1991Assignee: Sigma Chemical CompanyInventors: Kenneth J. Stenglein, Dennis M. Murray
-
Patent number: 5047318Abstract: A dye-providing composition is useful in various diagnostic assays wherein a peroxidase-labeled specific binding species is used. This composition is substantially free of peroxidase and such labeled species, and comprises an imidazole leuco dye and 4'-hydroxyacetanilide present in an amount up to about 2.5 mmolar. This composition can be included as part of a diagnostic test kit.Type: GrantFiled: June 13, 1988Date of Patent: September 10, 1991Assignee: Eastman Kodak CompanyInventors: Brian A. Snyder, Harold C. Warren, III, Gregory J. McClune
-
Patent number: 5035995Abstract: A substance-conjugated complement component C1q is provided. A substance such as signal emitting substances or cell function regulating substances is conjugated via a sulfur atom to at least one site of the component. The site is not involved in binding immunoglobulins. A marker-labelled complement component C1q is used for measuring a complement-binding antibody, an antigen, a neutralizing antibody or a substance produced internally of and at the surface of a cell or a microorganism by measuring the marker.Type: GrantFiled: May 22, 1989Date of Patent: July 30, 1991Assignees: Calpis Food Industry Co., Ltd., Fumiaki TaguchiInventors: Fumiaki Taguchi, Isamu Mitsui, Kinichi Hara, Masaro Hayashi, Kunio Ezawa, Kenichi Fukunaga, Jun Kuranari
-
Patent number: 5017472Abstract: This invention relates to a flotation immunoassay employing a novel buoyant matrix to which an antigen or antibody is coupled and which separates the bound and free products of the assay by floating to the surface of the reaction liquid. The novel flotation device which makes it possible to detect and to quantitate either antigen or antibody can also be used to fractionate cells and molecules.Type: GrantFiled: September 9, 1987Date of Patent: May 21, 1991Inventors: Richard B. Bankert, Elizabeth A. Repasky
-
Patent number: 4999284Abstract: A quartz crystal microbalance assay in which the binding of analyte to a surface on or near a quartz crystal microbalance (QCM) is detected by a conjugate which comprises an enzyme capable of catalyzing the conversion of a substrate to a product capable of accummulating on or reacting with a surface of the QCM leading to a mass change and, hence, a change in resonant frequency.Type: GrantFiled: April 6, 1988Date of Patent: March 12, 1991Assignee: E. I. Du Pont de Nemours and CompanyInventors: Michael D. Ward, Richard C. Ebersole
-
Patent number: 4981782Abstract: Synthetic polypeptides having influenza virus antigenic properties are disclosed. These polypeptides correspond substantially to particular regions in the matrix protein of influenza virus. Salts, derivatives, and conjugates of these polypeptides are disclosed as well as methods for using these materials for diagnostic and medical/veterinary purposes.Type: GrantFiled: May 14, 1987Date of Patent: January 1, 1991Assignee: SRI InternationalInventors: Amrit K. Judd, Doris J. Bucher, Steven W. Popple
-
Patent number: 4981979Abstract: Method for producing an immunoconjugate comprising the steps of reacting a toxin or protein with a heterobifunctional reagent having the following general formula: ##STR1## where R.sub.1 is: ##STR2## where n=1 to 10; and where R.sub.2 is selected from the group consisting of o- and p-nitrophenyl, 2-chloro-4-nitrophenyl, cyanomethyl, 2-mercaptopyridyl, hydroxybenztriazole, N-hydroxysuccinimide, trichlorophenyl, tetrafluorophenyl, 2-fluorophenyl, 4-fluoropheyl, 2,4-difluorophenyl, o-nitro-p-sulfophenyl, N-hydroxyphthalimide, N,N-diethylamino, N-hydroxypyrrolidone, tetrafluorothiophenyl, and 2,3,5,6-tetrafluorophenyl, under reactive conditions, thereby forming a derivatized toxin or protein.Type: GrantFiled: September 10, 1987Date of Patent: January 1, 1991Assignee: NeoRx CorporationInventor: Gowsala Sivam
-
Patent number: 4977079Abstract: An immunoenzimatic method is disclosed for the detection and the measurement of anti-P. falciparum sporzoite antibodies in human blood and/or in its derivatives, which operates with a synthetic antigen-enzyme conjugate capable of forming with the antisporozoite antibodies a stable antibody-synthetic antigen-enzyme complex, and one or more proteins absorbed and/or covalently linked to a solid support, which eagerly bind the antisporozoite antibody of said complex.The method, thanks to its simpleness, specificity and rapidity, is particularly useful in epidemiologic investigations into malaria and into the efficacy of an antimalarial vaccine.Type: GrantFiled: December 17, 1987Date of Patent: December 11, 1990Assignee: Eniricerche S.p.A.Inventors: Carlo A. Nuzzolo, Adriano Bernardi, Antonello Pessi, Antonio S. Verdini
-
Patent number: 4962187Abstract: A purified common antigen for colorectal and mucinous ovarian cancer (COTA) is provided which is antigenically distinct from CSAp, CEA and Ca 19-9. The COTA antigen is useful for producing a COTA antibody which is nonreactive with CSAp, CEA or Ca 19-9.Type: GrantFiled: November 21, 1986Date of Patent: October 9, 1990Assignee: Cota BiotechInventor: Keshab D. Pant
-
Patent number: 4959306Abstract: Methods and materials for preparing specific binding reagents with a multiplicity of relatively noninterfering label moieties are described. By spacing the labels at the surface of a specific reagent with bulking agent, increased sensitivity can be achieved without interference between individual labeling entities.Type: GrantFiled: November 28, 1986Date of Patent: September 25, 1990Assignee: Sclavo, Inc.Inventors: Naomi Kameda, Gerald L. Rowley
-
Patent number: 4954435Abstract: The method of the present invention employs an enzyme immunoassay for measuring the concentration of an analyte in a sample by indirect colorimetric detection. An incident light beam at a plurality of wavelengths is directed into a liquid solution containing an analyte of interest. The solution is capable of attenuating the amount of light at a first wavelength received from this solution as a function of the increasing concentration of the analyte present. A light signal from the solution at the first wavelength is detected, and light at a second wavelength, at which substantially no attenuation of light signal occurs as the concentration of the analyte increases, is also detected. The ratio of the two respective wavelengths is formed and that ratio is compared with ratios of known amounts of the analyte to determine the amount of the analyte in the sample.Type: GrantFiled: January 12, 1987Date of Patent: September 4, 1990Assignee: Becton, Dickinson and CompanyInventor: Gary H. Krauth
-
Patent number: 4954452Abstract: A method of performing a diagnostic immunoassay utilizing colloidal non-metal particles having conjugated thereto a binding component capable of specifically recognizing an analyte to be determined. After reaction of the sample and colloidal non-metal particles, the presence or amount of analyte/colloidal non-metal particle complexes are determined by optical analysis as a measure of the amount of analyte in the sample. The method can be utilized for the specific detection of numerous analytes and is sensitive and has a wide detection range.Type: GrantFiled: July 9, 1987Date of Patent: September 4, 1990Assignee: Abbott LaboratoriesInventors: David A. Yost, John C. Russell, Heechung Yang
-
Patent number: 4954630Abstract: The present invention provides resorufin derivatives of the general formulae: ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5, which can be the same or different, are hydrogen, halogen, carboxyl, carboxamido, lower alkoxycarbonyl, cyano or nitro groups or lower alkyl or lower alkoxy radicals, which can be substituted by carboxyl, carboxamido, lower alkoxycarbonyl, cyano or nitro groups, and wherein R.sup.4 and R.sup.5 can together also represent an anellated aromatic residue, Z is a bridge member, A is the residue of a ligand and n is a whole number of from 1 to 200.The present invention also provides processes for the preparation of these resorufin derivatives, as well as intermediates for the preparation thereof.Type: GrantFiled: July 24, 1986Date of Patent: September 4, 1990Assignee: Boehringer Mannheim GmbHInventors: Christian Klein, Hans-Georg Batz, Rupert Herrmann
-
Patent number: 4950588Abstract: A chemiluminescence process comprising the contacting of a chemiluminescence precursor, an oxidant, an enzyme, a chemiluminescence enhancer and a nitrogen compound selected from the group consisting of ammonia and water-soluble organic amines. The reaction of such process can be used in detection of nucleic acid hybrids, antibodies, antigens and peroxidase enzymes and in producing light.Type: GrantFiled: September 27, 1988Date of Patent: August 21, 1990Assignee: Molecular Diagnostics, Inc.Inventor: Nanibhushan Dattagupta
-
Patent number: 4950613Abstract: A method of preparing a labelled specific binding partner, such as a biological probe in the form of an antibody or oligonucleotide probe, using a protected label (the corresponding unprotected label being susceptible to inactivation, such as by hydrolysis to yield a non-chemiluminescent form of the label). The specific binding partner is linked to the label, and an adduct of the label is prepared using a protective adduct former which produces a protected label which is less susceptible to inactivation. Particularly preferred labels are the acridiniums and acridans, most preferably the former having the general structure: ##STR1## wherein the phenyl rings are optionally additionally substituted, R.sub.1 is preferably an alkyl, and R.sub.5 is an optionally substituted hydrocarbon, most preferably a phenyl moiety which is either linked to the specific binding partner, or capable of being linked thereto.Type: GrantFiled: February 26, 1988Date of Patent: August 21, 1990Assignee: Gen-Probe IncorporatedInventors: Lyle J. Arnold, Jr., Alexander A. Waldrop, III, Philip W. Hammond
-
Patent number: 4948725Abstract: Novel Fc receptors, denoted type VI, are disclosed as reacting with rat immunoglobulins with a reasonable affinity. These receptors, or the microorganisms which produce them, are useful in immunoassays.Type: GrantFiled: December 10, 1987Date of Patent: August 14, 1990Assignee: University of Florida Research Foundation, Inc.Inventor: Michael D. P. Boyle
-
Patent number: 4942123Abstract: This invention relates in general to a phosphoprotein product of the retinoblastoma susceptibility gene. In particular, this invention relates to a phosphoprotein ppRB.sup.110 primarily located in the cell nucleus which has a DNA binding activity. The invention also relates to the amino acid sequence of the phosphoprotein and to the specific purified anti-retinoblastoma phosphoprotein antibody. The invention further relates to a method of diagnosing retinoblastoma and other retinoblastoma gene involved cancers, treating such kind of cancers and regulating the oncogenicity of other genes.Type: GrantFiled: September 17, 1987Date of Patent: July 17, 1990Assignee: The Regents of the University of CaliforniaInventors: Wen-Hwa Lee, Eva Y. - H. P. Lee
-
Patent number: 4940669Abstract: A sac, in particular a vesicle, having a detectable metal, in particular a rear earth metal, encapsulated therein. The sac may be sensitized with a ligand and used in an assay. The vesicle is stored and/or used in an aqueous solution which includes the rare earth metal to increase the concentration of metal in the sac.Type: GrantFiled: May 15, 1987Date of Patent: July 10, 1990Assignee: Becton Dickinson and CompanyInventors: Daniel B. Wagner, Glenn P. Vonk
-
Patent number: 4935407Abstract: Thermochemiluminescent complexes of an adamanthylideneadamantane 1,2-dioxetane and a cyclodextrin are non-volatile at the temperatures used to excite the thermochemiluminescence. The complexes can be encapsulated in immunosensitized microcapsules, e.g., liposomes, to provide a labeled immunoreagent useful in immunoassay using thermochemiluminescent labeled immunoreagents.Type: GrantFiled: September 22, 1987Date of Patent: June 19, 1990Assignee: Akzo N.V.Inventors: Theo M. Luider, Jan C. Hummelen, Johannes N. Koek, Hans Wynberg
-
Patent number: 4927769Abstract: A method for enhancing the chemiluminescent signal of an acridinium ester in a chemiluminescent reaction which comprises oxidizing the acridinium ester in the presence of an enhancer selected from the group consisting of: (a) a cationic surfactant; (b) a nonionic surfactant; and (c) a sulfated primary alcohol.Type: GrantFiled: July 8, 1987Date of Patent: May 22, 1990Assignee: Ciba Corning Diagnostics Corp.Inventors: Steve C. S. Chang, Thomas E. Miller
-
Patent number: 4921808Abstract: The present disclosure relates to an improved method based on hormone-receptor binding for the determination of follicle stimulating hormone and to improved reagents useful for the determination of follicle stimulating hormone in a hormone-receptor binding assay.Type: GrantFiled: June 25, 1986Date of Patent: May 1, 1990Assignee: The Albany Medical College of Union UniversityInventors: Alan L. Schneyer, Patrick M. Sluss, Bosukonda Dattatreyamurty, Leo E. Reichert, Jr.
-
Patent number: 4904583Abstract: A method for enzyme immunoassay includes contacting under binding conditions a liquid suspected of containing an analyte, an antianalyte affixed to a solid support and a tracer having an enzyme conjugated thereto. A bound fraction is separated from the liquid and incubated in a second liquid with a masked ligand. The masked ligand is converted by the enzyme on the bound fraction to give free lignad which binds to an antiligand. A signal system, such as a signal enzyme and substrate therefor, or a label-loaded vesicle and vesicle lysing agent, is added to generate a signal used to detect or measure the analyte in the liquid. The invention includes a kit of materials useful in performing the assay of the invention.Type: GrantFiled: May 26, 1987Date of Patent: February 27, 1990Assignee: Becton, Dickinson and CompanyInventors: James P. Mapes, Randal A. Hoke
-
Patent number: 4900664Abstract: A method is provided for detecting and measuring acetaldehyde-protein condensates. An antibody is produced to an antigen, the antibody being cross-reactive with acetaldehyde-protein condensates, these condensates including protein moieties corresponding to or different from the protein moiety of the antigen. Detection and measurement of acetaldehyde-protein condensates may be performed by reacting the antibody with the acetaldehyde-protein condensate to form a complex and measuring the complex.Type: GrantFiled: October 2, 1986Date of Patent: February 13, 1990Assignee: Alcoholism and Drug Addition Research FoundationInventors: Yedy Israel, Ruth Arnon
-
Patent number: 4879248Abstract: An immunoassay for trichothecenes that have at least three hydroxyl groups at specified positions is disclosed. It relies on developing antibodies to close trichothecene variants that are missing at least one of the hydroxyl groups, and then using these antibodies to test specimens in which the trichothecene has been converted to the variant (usually to the OAC variant). For example, DON and T-2 tetraol can be assayed for using this invention.Type: GrantFiled: April 28, 1987Date of Patent: November 7, 1989Assignee: Wisconsin Alumni Research FoundationInventors: Fun S. Chu, Ru-Dong Wei, Guang S. Zhang
-
Patent number: 4879249Abstract: Novel immunoassay which utilizes an enzyme linked ligand or receptor wherein the enzyme is bacterial luciferase; mercantile kit useful in performing said immunoassay; and compounds utilized in performing said assay.Type: GrantFiled: March 17, 1986Date of Patent: November 7, 1989Inventors: Thomas O. Baldwin, Thomas F. Holzman, Paul S. Satoh, Frederick S. Yein
-
Patent number: 4874693Abstract: A method is presented for detecting placental dysfunction that is diagnostic of aneuploid chromsomal abnormalities. It is particularly useful for diagnosing pregnancies at risk for fetal aneuploid chromosome abnormalities, and consists of quantitating the hormone human chroionic gonadotropin (HCG) alone or in combination with the free alpha subunit of HCG (alpha-HCG). In a preferred embodiment of the invention, bodily fluids from women between 18 and 25 weeks of gestation are assayed using an immunoassay. Levels of 2.5 or more multiples of the median value for normal pregnancies (MOM) for HCG and/or alpha-HCG are indicative of fetal chromosome abnormalities. This test will detect approximately 70% of fetuses with chromosome aneuploidy.Type: GrantFiled: October 10, 1986Date of Patent: October 17, 1989Inventor: Mark Bogart
-
Patent number: 4855226Abstract: A novel competitive assay for theophylline wherein caffeine-like (7-substituted) labeled conjugates are used to detect the presence and/or amount of theophylline present in a test sample. The use of such conjugates in a competitive assay for theophylline results in improved sensitivity of the assay method. Where the assay method is a nephelometric or turbidimetric inhibition immunoassay procedure, the assay was found to be less temperature dependent than prior art immunoassays.Type: GrantFiled: June 7, 1985Date of Patent: August 8, 1989Assignee: Beckman Instruments, Inc.Inventors: Alan J. Polito, Anthony K. Cheng
-
Patent number: 4851334Abstract: Hybridoma for production of monoclonal antibody to an antigen found on the peptide fragment of the B.beta. chain of human fibrinogen or fibrin I containing amino acid residues 1-42. The hybridoma is formed by fusing an animal myeloma cell, e.g., mouse myeloma cell, with a splenocyte from an animal, e.g., a mouse, immunized with an NH.sub.2 -terminal of human fibrinogen or fibrin I. Hybridoma for production of monoclonal antibody to an antigen found on the peptide fragment of the B.beta. chain of human fibrin II containing amino acid residues 15-42. The hybridoma is formed by fusing an animal, e.g., mouse myeloma cell with a splenocyte from an animal, e.g., mouse, immunized with a NH.sub.2 -terminal of human fibrin II. Diagnostic and therapeutic uses of the monoclonal antibodies are also disclosed.Type: GrantFiled: August 10, 1987Date of Patent: July 25, 1989Assignee: The New York Blood Center, Inc.Inventors: Bohdan J. Kudryk, Michael E. Wiebe
-
Patent number: 4843019Abstract: The invention relates to acino-fetal differentiation proteins associated with cancer of the pancreas, these proteins being mannoside-containing glycoproteins of average apparent molecular mass chosen from: 120 KD, 94 KD and 58 KD.The invention also relates to a method for preparing these proteins, an antiserum against these proteins and the method for preparation thereof, monoclonal antibodies against these proteins and the method for preparation thereof, and compositions for diagnostic or therapeutic use containing these proteins or antibodies.Type: GrantFiled: May 29, 1986Date of Patent: June 27, 1989Assignee: Centre National de la Recherche ScientifiqueInventors: Maria J. Escribano-Crespo, Pierre Burtin
-
Patent number: 4833073Abstract: Novel cannabinol derivatives are provided which can be used in improved immunoassays for the detection in blood or urine samples of cannabinol metabolites.Type: GrantFiled: January 27, 1987Date of Patent: May 23, 1989Assignee: Hoffmann-La Roche Inc.Inventors: Alan J. McNally, Alan Schwartz, Magdalena Usategui
-
Patent number: 4818683Abstract: The invention relates to a method of immunoassay for monoamines (molecules having a primary or secondary amine function) comprising chemical quantitative conversion of such amines into derivatives of higher molecular weight, which thereafter are brought into competition with radioactive analogous, or analogous carrying a tracer, for fixation to an antibody capable of recognizing all of them.Type: GrantFiled: August 6, 1987Date of Patent: April 4, 1989Assignee: ImmunotechInventors: Anne Morel, Michel Delaage
-
Patent number: 4791055Abstract: The reactant advantageously is an enzymatic reactant such as an enzyme substrate or coenzyme. The activity of the conjugated reactant as a constituent of a predetermined reaction is affected by reaction between the specific binding substance in the conjugate and a specific binding counterpart thereto. The presence of a ligand in a liquid medium may be determined using competitive or displacement binding or sequential saturation techniques wherein the specific binding substance in the conjugate is the ligand or a specific binding analog thereof, or using a direct binding technique wherein the specific binding substance is a specific binding partner of the ligand. The effect of the specific binding reaction on the activity of the conjugated reactant is related to the presence or amount of the ligand in the liquid medium tested.Type: GrantFiled: January 9, 1986Date of Patent: December 13, 1988Assignee: Miles Inc.Inventors: Robert C. Boguslaski, Robert J. Carrico, James E. Christner
-
Patent number: 4775745Abstract: This invention relates to a diazonium compound of the formula: ##STR1## wherein Z is selected from the group consisting of biotin, an antigen, an antibody, a photoreactive group, a fluorescent group and heavy metal-containing compounds;X is an alkylene group containing up to 18 carbon atoms in the principle chain and a total of up to 24 carbon atoms or a substituted alkylene group containing up to 18 carbon atoms in the principle chain with substituents selected from the group consisting of solubility-enhancing groups and cleavable --S--S-- containing moieties;Ar is an unsubstituted or substituted aryl or heteroaryl; andY is an anion and n is an integer from 1-3.Such compounds are useful as components for nucleic acid probes.Type: GrantFiled: December 8, 1986Date of Patent: October 4, 1988Assignee: National Distillers and Chemical CorporationInventors: John P. Ford, Bernard F. Erlanger, C. William Blewett
-
Patent number: 4770995Abstract: A process for predicting the sensitivity of cells, e.g., tumor cells, to the effects of tumor necrosis factor or lymphotoxin involving ascertaining the binding of the tumor necrosis factor or lymphotoxin to the cells, i.e., measuring the number of receptors on the cells.Type: GrantFiled: August 29, 1985Date of Patent: September 13, 1988Assignees: New York Blood Center, Inc, Sloan-Kettering Institute for Cancer ResearchInventors: Berish Y. Rubin, Sylvia L. Anderson, Susan A. Sullivan, Lloyd J. Old, Barbara D. Williamson, Elizabeth C. Richards
-
Patent number: 4761368Abstract: A new and useful fluorescent chromophore has been isolated and identified which has been observed in proteins exposed to glucose over time, and whose fluorescent properties closely resemble those of the polypeptide after it undergoes advanced glycosylation. The chromophore has been structurally identified and named 2-furoyl-4(5)-(2-furanyl)-1H-imidazole, and is believed to be one of the end products of extended nonenzymatic polypeptide glycosylation, which results in the state known as nonenzymatic browning (NEB). The measurement of this chromophore makes possible both qualitative and quantitative assessment of the degree of aging. Diagnostic and test kits are also disclosed.Type: GrantFiled: July 15, 1986Date of Patent: August 2, 1988Assignee: The Rockefeller UniversityInventor: Anthony Cerami
-
Patent number: 4752569Abstract: Detection of sialylated Lewis.sup.x antigen in sera is employed as diagnostic of the presence of cancer. Conveniently, monoclonal antibodies are provided which are shown to be useful in the diagnosis of a neoplastic condition, with a wide variety of different tumors.The hybridoma CSLEX1 was deposited at the A.T.C.C. on June 20, 1984 and given Accession No. HB8580.Type: GrantFiled: June 21, 1984Date of Patent: June 21, 1988Assignee: The Regents of the University of CaliforniaInventors: Paul I. Terasaki, Masaki Hirota, Kiyoyasu Fukushima, Akemi Wakisaka, Takashi Iguro
-
Patent number: 4745077Abstract: The invention concerns assays, such a immunoassays or two-site immunometric assays, performed using a labelled reagent and another reagent bound to magnetically attractable particles which are suspendable but insoluble in a liquid assay medium. After the labelled reagent has become partitioned between the liquid phase and the particles, in proportions which depend on the concentration of an analyte in a sample, the liquid phase is removed. Then the particles are re-suspended in another liquid medium, and the concentration of label observed. The method is particularly suitable for fluorescent and chemiluminescent' label systems, and can conveniently be performed in microtiter plates in which the wells are optically screened from one another, the observations being made from above or below the wells.Type: GrantFiled: January 17, 1985Date of Patent: May 17, 1988Assignee: Amersham International plc.Inventors: John Holian, John C. Edwards, John K. Martin, Stephen A. Charles
-
Patent number: 4743678Abstract: A first glycoprotein having a molecular weight of approximately 61,000-68,000 daltons in the MJ, C5-MJ, C91 PL or HUT-102 cell lines, of which 46,000 to 48,000 is the unglycosylated moiety, is obtained from cells infected with human T cell leukemia virus. A second glycoprotein having a molecular weight of approximately 45,000-52,000 daltons is also obtained from such cells and is in large part identical to the NH.sub.2 -terminal end of the first glycoprotein. The presence, in a biological specimen, of antibody to the antigenic determinant of either of these proteins is indicative of the presence of cells infected by human T cell leukemia virus. An assay for the antibody is a useful diagnostic procedure for determining such infection in biologial specimens.Type: GrantFiled: April 13, 1984Date of Patent: May 10, 1988Assignee: President and Fellows of Harvard CollegeInventors: Myron E. Essex, Tun-Hou Lee
-
Patent number: 4732862Abstract: A method is disclosed for the determination of human serum factors which are specific for human carcinomata antigens, in which method the serum of a patient with a carcinoma is incubated with CEA that has been radioactively labeled and anti-goat immunoglobulin serum in toto or depleted of the cross-reaction capacity for human IgA, IgG and IgM is added, then the whole mass is incubated and centrifugated, the supernatant is decanted and the precipitate is counted with a gamma counter. These specific serum factors are employed as a marker of primitive tumoral forms.Type: GrantFiled: November 14, 1984Date of Patent: March 22, 1988Inventor: Alberto Bartorelli
-
Patent number: 4719176Abstract: An enzyme-free diagnostic reagent, methods of its use and diagnostic systems containing that reagent are disclosed. The enzyme-free diagnostic reagent comprises an enzyme-free catalyst coupled by a linking group to a first binding agent, binds in aqueous medium to a second binding moiety to form a binding complex, and indicates the amount of second binding moiety present in the complex by means of its catalytic reactivity with co-reactant molecules.Type: GrantFiled: October 31, 1983Date of Patent: January 12, 1988Inventor: Irving M. Klotz